4.7 Article

Adaptor protein Lnk binds to and inhibits normal and leukemic FLT3

期刊

BLOOD
卷 120, 期 16, 页码 3310-3317

出版社

AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2011-10-388611

关键词

-

资金

  1. National Institutes of Health [R01CA026038-32, U54CA143930, 2P01 HL073104-060]
  2. Agency for Science, Technology, and Research (A*STAR
  3. investigator grant)
  4. Oncogenic Networks
  5. Deutsche Krebshilfe Stiftung
  6. Freie und Hansestadt Hamburg
  7. German Federal Ministry of Health

向作者/读者索取更多资源

Fms-like tyrosine kinase 3 (FLT3) is a receptor tyrosine kinase with important roles in hematopoietic progenitor cell survival and proliferation. It is mutated in approximately one-third of AML patients, mostly by internal tandem duplications (ITDs). Adaptor protein Lnk is a negative regulator of hematopoietic cytokine signaling. In the present study, we show that Lnk interacts physically with both wildtype FLT3 (FLT3-WT) and FLT3-ITD through the SH2 domains. We have identified the tyrosine residues 572, 591, and 919 of FLT3 as phosphorylation sites involved in direct binding to Lnk. Lnk itself was tyrosine phosphorylated by both FLT3 ligand (FL)-activated FLT3-WT and constitutively activated FLT3-ITD. Both shRNA-mediated depletion and forced overexpression of Lnk demonstrated that activation signals emanating from both forms of FLT3 are under negative regulation by Lnk. Moreover, Lnk inhibited 32D cell proliferation driven by different FLT3 variants. Analysis of primary BM cells from Lnk-knockout mice showed that Lnk suppresses the expansion of FL-stimulated hematopoietic progenitors, including lymphoid-primed multipotent progenitors. The results of the present study show that through direct binding to FLT3, Lnk suppresses FLT3-WT/ITD-dependent signaling pathways involved in the proliferation of hematopoietic cells. Therefore, modulation of Lnk expression levels may provide a unique therapeutic approach for FLT3-ITD-associated hematopoietic disease. (Blood. 2012;120(16):3310-3317)

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Cell Biology

Phosphoproteomics of primary AML patient samples reveals rationale for AKT combination therapy and p53 context to overcome selinexor resistance

Kristina B. Emdal, Nicolas Palacio-Escat, Caroline Wigerup, Akihiro Eguchi, Helen Nilsson, Dorte B. Bekker-Jensen, Lars Ronnstrand, Julhash U. Kazi, Alexandre Puissant, Raphael Itzykson, Julio Saez-Rodriguez, Kristina Masson, Peter Blume-Jensen, Jesper V. Olsen

Summary: In this study, the signaling responses of Selinexor in AML patients and cell lines were investigated using phosphoproteomics. The study identified key targetable signaling hubs for rational drug combinations by scoring the phosphorylation sites of P53. Furthermore, combining Selinexor with AKT inhibitor MK-2206 overcame dysregulated AKT-FOXO3 signaling in resistant cells, resulting in synergistic anti-proliferative effects.

CELL REPORTS (2022)

Article Chemistry, Multidisciplinary

An Integrated Polymeric mRNA Vaccine without Inflammation Side Effects for Cellular Immunity Mediated Cancer Therapy

Pei Huang, Lingsheng Jiang, Hui Pan, Lingwen Ding, Bo Zhou, Mengyao Zhao, Jianhua Zou, Benhao Li, Meiwei Qi, Hongzhang Deng, Yongfeng Zhou, Xiaoyuan Chen

Summary: Researchers synthesized a new polymer for mRNA delivery, which showed no inflammatory side effects in vivo and successfully delivered mRNA cancer vaccines, resulting in robust anti-tumor cellular immune response.

ADVANCED MATERIALS (2023)

Article Oncology

Targeting RNA Exonuclease XRN1 Potentiates Efficacy of Cancer Immunotherapy

Xue-Bin Ran, Ling-Wen Ding, Qiao-Yang Sun, Henry Yang, Jonathan W. Said, Lao Zhentang, Vikas Madan, Pushkar Dakle, Jin-Fen Xiao, Xinyi Loh, Ying Li, Liang Xu, Xiao-Qiang Xiang, Ling-Zhi Wang, Boon Cher Goh, De-Chen Lin, Wee Joo Chng, Soo-Yong Tan, Sudhakar Jha, H. Phillip Koeffler

Summary: Despite the limited response rate of immune checkpoint blockade therapy, targeting RNA decay machinery by silencing XRN1 can sensitize tumor cells to immunotherapy by activating IFN signaling and the viral defense pathway. XRN1 depletion triggers aberrant RNA-mediated IFN signaling and has the potential to be effective in multiple types of cancers. These findings provide a molecular rationale for developing XRN1 inhibitors and combining them with cancer immunotherapy.

CANCER RESEARCH (2023)

Article Medicine, Research & Experimental

FAM3C in circulating tumor-derived extracellular vesicles promotes non-small cell lung cancer growth in secondary sites

Win Lwin Thuya, Li Ren Kong, Nicholas L. Syn, Ling -Wen Ding, Esther Sok Hwee Cheow, Regina Tong Xin Wong, Tingting Wang, Robby Miguel Wen-Jing Goh, Hongyan Song, Migara K. Jayasinghe, Minh T. N. Le, Jian Cheng Hu, Wei-Peng Yong, Soo-Chin Lee, Andrea Li-Ann Wong, Gautam Sethi, Huynh The Hung, Paul Chi-Lui Ho, Jean-Paul Thiery, Siu Kwan Sze, Tiannan Guo, Ross A. Soo, Henry Yang, Yaw Chyn Lim, Lingzhi Wang, Boon-Cher Goh

Summary: This study reveals that the cargo protein FAM3C carried by tumor-released extracellular vesicles (EVs) can enhance the growth and metastatic potential of lung cancer cells. FAM3C interacts with RalA protein to activate the Src/Stat3 signaling pathway, promoting oncogenicity. This finding provides a new target for lung cancer therapy.

THERANOSTICS (2023)

Article Biochemistry & Molecular Biology

A deep tabular data learning model predicting cisplatin sensitivity identifies BCL2L1 dependency in cancer

Ahmad Nasimian, Mehreen Ahmed, Ingrid Hedenfalk, Julhash U. Kazi

Summary: In this study, a gene signature was defined through the analysis of cisplatin-perturbed gene expression and pathway enrichment, and a cisplatin sensitivity prediction model was developed using the TabNet algorithm. The TabNet model outperformed other machine learning models with an accuracy of over 80%. Furthermore, BCL2L1 was identified as an important gene contributing to cisplatin resistance, and its pharmacological inhibition was found to enhance cisplatin efficacy. This study developed a tool to predict cisplatin sensitivity and identified BCL2L1 as a significant gene in this context.

COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL (2023)

Article Biochemistry & Molecular Biology

A Receptor Tyrosine Kinase Inhibitor Sensitivity Prediction Model Identifies AXL Dependency in Leukemia

Ahmad Nasimian, Lina Al Ashiri, Mehreen Ahmed, Hongzhi Duan, Xiaoyue Zhang, Lars Roennstrand, Julhash U. Kazi

Summary: Despite progress in cancer treatment, therapy resistance remains a major obstacle for long-term survival. By using highly variable genes and pharmacogenomic data, a drug sensitivity prediction model for the tyrosine kinase inhibitor sorafenib was developed with over 80% accuracy. AXL was identified as an important feature for drug resistance and PKC signaling was found to be enriched in drug-resistant patient samples. Inhibition of tyrosine kinase activity enhanced AXL expression and phosphorylation of the PKC-substrate CREB protein, showing synergy with AXL and PKC inhibitors.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Article Biochemistry & Molecular Biology

Venetoclax-Resistant T-ALL Cells Display Distinct Cancer Stem Cell Signatures and Enrichment of Cytokine Signaling

Kinjal Shah, Lina Al Ashiri, Ahmad Nasimian, Mehreen Ahmed, Julhash U. Kazi

Summary: Therapy resistance in cancer treatment, specifically T-cell acute lymphoblastic leukemia (T-ALL), is linked to the deregulation of the anti-apoptotic protein BCL2 and is mediated through distinct gene signatures and cytokine signaling pathways. Different T-ALL cell lines display varying response to BCL2 inhibition, and prolonged exposure to venetoclax leads to the development of resistance. The expression of BCL2 family genes and global gene expression profiles, including cancer stem cell-related genes, differ between resistant cells and sensitive cells.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Article Hematology

Antiphospholipid antibodies in convalescent plasma of donors recovered from mild COVID-19 infection

Dorit Blickstein, Marina Izak, Talia Filipovich-Rimon, Osnat Garach-Jehoshua, Naomi Rahimi-Levene, Eilat Shinar, Ramzia Abu Hamad, Adina Bar-Chaim, Maya Koren-Michowitz

Summary: This study aimed to evaluate the prevalence of antiphospholipid antibodies (APLA) in convalescent plasma (CP) obtained from COVID-19 patients and assess the potential risk of thrombosis in transfused patients. The results showed that out of 122 CP samples, 7 samples (6%) tested positive for APLA. The low prevalence of APLA in CP donors reassured the safety of CP administration to patients with severe COVID-19.

VOX SANGUINIS (2023)

Article Biochemistry & Molecular Biology

Chemo-Enzymatic Fluorescence Labeling Of Genomic DNA For Simultaneous Detection Of Global 5-Methylcytosine And 5-Hydroxymethylcytosine

Sigal Avraham, Leonie Schuetz, Larissa Kaever, Andreas Dankers, Sapir Margalit, Yael Michaeli, Shahar Zirkin, Dmitry Torchinsky, Noa Gilat, Omer Bahr, Gil Nifker, Maya Koren-Michowitz, Elmar Weinhold, Yuval Ebenstein

Summary: The article presents a new high-throughput platform for multi-color epigenetic analysis, which allows simultaneous detection of methylation and demethylation signals. By utilizing an engineered methyltransferase enzyme and enzymatic glycosylation, the study achieves simultaneous measurement of 5-hydroxymethylcytosine and 5-methylcytosine. The findings demonstrate the potential of using a simple blood test for epigenetic evaluation in clinical samples, benefiting research and patient management.

CHEMBIOCHEM (2023)

Article Biochemistry & Molecular Biology

DDR1/2 enhance KIT activation and imatinib resistance of primary and secondary KIT mutants in gastrointestinal stromal tumors

Anbu Liu, Shaoting Zhang, Ming Wang, Liangying Zhang, Shidong Xu, Ahmad Nasimian, Shujing Li, Sien Zhao, Xu Cao, Jinhai Tian, Yuanyuan Yu, Zhaoyang Fan, Kun Xiao, Hui Zhao, Julhash U. Kazi, Lijun Ma, Jianmin Sun

Summary: This study demonstrates that DDR1/2 contribute to KIT activation and enhance resistance to imatinib in GISTs, providing a rationale for further exploration of DDR1/2 targeting in GIST treatment.

MOLECULAR CARCINOGENESIS (2023)

Article Oncology

MicroRNA Landscape in Endometrial Carcinomas in an Asian population: Unraveling Subtype-Specific Signatures

Gideon Ze Lin Tan, Sai Mun Leong, Yu Jin, Chik Hong Kuick, Jeremy Joon Keat Chee, San Zeng Low, Ling-Wen Ding, He Cheng, Diana Lim, Susan Swee-Shan Hue

Summary: In this study, we analyzed the expression of microRNAs in endometrial carcinomas and found differential expression profiles among different subtypes and molecular subtypes. These findings may have implications for the development of diagnostic and prognostic tools for endometrial carcinoma.

CANCERS (2023)

Article Medicine, General & Internal

Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study

Srdan Verstovsek, Aaron T. Gerds, Alessandro M. Vannucchi, Haifa Kathrin Al-Ali, David Lavie, Andrew T. Kuykendall, Sebastian Grosicki, Alessandra Iurlo, Yeow Tee Goh, Mihaela C. Lazaroiu, Miklos Egyed, Maria Laura Fox, Donal McLornan, Andrew Perkins, Sung -Soo Yoon, Vikas Gupta, Jean -Jacques Kiladjian, Nikki Granacher, Sung-Eun Lee, Luminita Ocroteala, Francesco Passamonti, Claire N. Harrison, Barbara J. Klencke, Sunhee Ro, Rafe Donahue, Jun Kawashima, Ruben Mesa

Summary: This study aimed to compare the clinical effects of momelotinib and danazol in patients with intermediate or high-risk myelofibrosis. The results showed that momelotinib can significantly improve myelofibrosis-associated symptoms, anemia measures, and spleen response compared to danazol, with favorable safety.

LANCET (2023)

Article Oncology

Understanding the Role of Activation Loop Mutants in Drug Efficacy for FLT3-ITD

Julhash U. Kazi, Lina Al Ashiri, Rituraj Purohit, Lars Ronnstrand

Summary: This study investigated the impact of FLT3 mutations on its function and interaction with therapeutic drugs in acute myeloid leukemia (AML). The findings provide insights for tailored treatments and highlight the significance of customized medical approaches in AML therapy.

CANCERS (2023)

Review Rheumatology

Ruxolitinib for Refractory Macrophage Activation Syndrome Complicating Adult-Onset Still's Disease

Ofer Levy, Arie Apel, Hossam Alhdor, Avraham Mizrachi, Nancy Agmon-Levin, Maya Koren-Michowitz, Mirit Amit-Vazina

Summary: The translation mentions a case of a patient with adult-onset Still's disease who did not respond to conventional medications but miraculously responded to salvage therapy with ruxolitinib. The article reviews recent data related to the therapeutic value of ruxolitinib for macrophage activation syndrome triggered by adult-onset Still's disease.

EUROPEAN JOURNAL OF RHEUMATOLOGY (2022)

暂无数据